Athena Sharifi-Razavi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Athena Sharifi-Razavi has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Abdoreza Ghoreishi
Stroke Research Group, Head of Stroke Care Unit, Department of Neurology, Vali-E-Asr Hospital, School of Medicine, Zanjan University of Medical Science, Zanjan, Iran
2 shared publications Amir Moghadam Ahmadi
Thomas Jefferson Univ, Vickie & Jack Farber Inst Neurosci, Jefferson Weinberg ALS Ctr, Philadelphia, PA USA
2 shared publicationsAshraf Zarvani
Clinical Research Development Unit of Bu-Ali Sina Hospital, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2 shared publicationsFatemeh Ramezanpour
Mazandaran Univ Med Sci, Dept Neurolody, Pharmaceut Sci Res Ctr, Sari, Iran
2 shared publications- Mana Baziboroun
Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medial Sciences, Tehran, Iran
2 shared publications Monireh Ghazaeian
Pharmaceutical Research Center, Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
2 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by Elsevier in SSRN Electronic Journal
Intravenous Thrombolysis for Acute Ischemic Stroke Across the Middle East and North Africa (2021–2023): Results from the SITS-MENA Registry
Background: Intravenous thrombolysis (IVT) for acute ischemic stroke in the Middle-East and North African (MENA) countries has increased in the last decade, but long-term outcomes and quality of care are less well studied. Methods: This was a prospective observational study to examine 3-month outcomes of IVT-treated patients in MENA stroke units using the SITS Registry. Findings: There were 2768 patients in MENA and 7163 patents in non-MENA treated with IVT and registered in SITS between August 2021 and September 2023. Compared to non-MENA, MENA patients were younger (65 vs 72 years-old), had higher NIH Stroke Scale scores at baseline (11 vs 9) and shorter door-to-needle times (30 vs 54 min). The most common risk factors in MENA were hypertension (64.9 vs 69.8 %) and diabetes (30.8 vs 20.1%). Functional independence at 3 months was similar (56.6% vs 57.7%); however, mortality at 7 and 30 days was significantly higher in MENA (8.3% vs 5.3% and 20.7 vs 14.5%). Symptomatic intracranial hemorrhage rates were low in both groups (<1.2% per SITS-MOST). Early mortality rates related to stroke were comparable (56.7 vs 59.2%) but early deaths caused by myocardial infarction, pneumonia, pulmonary embolism and sepsis were more frequent in MENA (14.2 vs 4.6%, 6.7 vs 4.6%, 1.5 vs 0.4% and 3 vs 1.8%). Interpretation: The overall mortality of IVT-treated patients was increased in MENA at 7 and 90 days post-stroke. Differences in risk factors at baseline may account for mortality but the treatment of medical complications in MENA stroke units warrants further study.
- 28 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIntravenous Thrombolysis for Acute Ischemic Stroke Across the Middle East and North Africa (2021–2023): Results from the SITS-MENA Registry
Background: Intravenous thrombolysis (IVT) for acute ischemic stroke in the Middle-East and North African (MENA) countries has increased in the last decade, but long-term outcomes and quality of care are less well studied. Methods: This was a prospective observational study to examine 3-month outcomes of IVT-treated patients in MENA stroke units using the SITS Registry. Findings: There were 2768 patients in MENA and 7163 patents in non-MENA treated with IVT and registered in SITS between August 2021 and September 2023. Compared to non-MENA, MENA patients were younger (65 vs 72 years-old), had higher NIH Stroke Scale scores at baseline (11 vs 9) and shorter door-to-needle times (30 vs 54 min). The most common risk factors in MENA were hypertension (64.9 vs 69.8 %) and diabetes (30.8 vs 20.1%). Functional independence at 3 months was similar (56.6% vs 57.7%); however, mortality at 7 and 30 days was significantly higher in MENA (8.3% vs 5.3% and 20.7 vs 14.5%). Symptomatic intracranial hemorrhage rates were low in both groups (<1.2% per SITS-MOST). Early mortality rates related to stroke were comparable (56.7 vs 59.2%) but early deaths caused by myocardial infarction, pneumonia, pulmonary embolism and sepsis were more frequent in MENA (14.2 vs 4.6%, 6.7 vs 4.6%, 1.5 vs 0.4% and 3 vs 1.8%). Interpretation: The overall mortality of IVT-treated patients was increased in MENA at 7 and 90 days post-stroke. Differences in risk factors at baseline may account for mortality but the treatment of medical complications in MENA stroke units warrants further study.
- Open Access
- 29 September 2025
- Published by Springer Nature in BMC Neurology
- Vol. 25 (1) , 1-7
Low-dose vs. standard-dose alteplase for acute ischemic stroke: a retrospective cohort study of safety and efficacy in an Iranian population
The optimal dosing of alteplase for acute ischemic stroke remains debated, particularly regarding the balance between efficacy and bleeding risks. This study compared outcomes between standard-dose (0.9 mg/kg) and low-dose (< 0.85 mg/kg) alteplase in an Iranian cohort. In this retrospective cohort study, 328 patients with acute ischemic stroke treated at Boo-Ali Sina Hospital (2016–2023) were analyzed. Participants were divided into standard-dose (n = 177) and low-dose (n = 151) groups. Primary outcomes included functional independence (modified Rankin Scale [mRS] 0–2 at 3 months) and symptomatic intracranial hemorrhage (sICH). Secondary outcomes comprised mortality and hemorrhagic complications. Multivariable logistic regression adjusted for age, NIHSS score, and comorbidities. The low-dose group had significantly lower rates of sICH (5.29% vs. 13.55%, p = 0.01), fatal bleeding (1.98% vs. 7.90%, p = 0.03), and in-hospital mortality (8.6% vs. 15.81%, p = 0.01). Parenchymal hemorrhage-1 occurred exclusively with standard dosing (15.9% vs. 0%). Three-month functional outcomes were comparable (mRS 0–2: 53.6% vs. 46.9%, p = 0.22). Adjusted analyses confirmed reduced odds of any ICH (OR 0.34, 95% CI 0.18–0.64) and fatal ICH (OR 0.23, 95% CI 0.06–0.83) with low-dose therapy. Low-dose alteplase was associated with fewer hemorrhagic complications and lower mortality while maintaining comparable functional outcomes to standard dosing. These findings support its potential as a safer alternative, particularly in resource-limited settings where cost and drug availability pose challenges. Randomized trials are needed to validate these results.
- 29 September 2025
- Published by Springer Nature in BMC Neurology
- Vol. 25 (1) , 1-7
Open AccessLow-dose vs. standard-dose alteplase for acute ischemic stroke: a retrospective cohort study of safety and efficacy in an Iranian population
The optimal dosing of alteplase for acute ischemic stroke remains debated, particularly regarding the balance between efficacy and bleeding risks. This study compared outcomes between standard-dose (0.9 mg/kg) and low-dose (< 0.85 mg/kg) alteplase in an Iranian cohort. In this retrospective cohort study, 328 patients with acute ischemic stroke treated at Boo-Ali Sina Hospital (2016–2023) were analyzed. Participants were divided into standard-dose (n = 177) and low-dose (n = 151) groups. Primary outcomes included functional independence (modified Rankin Scale [mRS] 0–2 at 3 months) and symptomatic intracranial hemorrhage (sICH). Secondary outcomes comprised mortality and hemorrhagic complications. Multivariable logistic regression adjusted for age, NIHSS score, and comorbidities. The low-dose group had significantly lower rates of sICH (5.29% vs. 13.55%, p = 0.01), fatal bleeding (1.98% vs. 7.90%, p = 0.03), and in-hospital mortality (8.6% vs. 15.81%, p = 0.01). Parenchymal hemorrhage-1 occurred exclusively with standard dosing (15.9% vs. 0%). Three-month functional outcomes were comparable (mRS 0–2: 53.6% vs. 46.9%, p = 0.22). Adjusted analyses confirmed reduced odds of any ICH (OR 0.34, 95% CI 0.18–0.64) and fatal ICH (OR 0.23, 95% CI 0.06–0.83) with low-dose therapy. Low-dose alteplase was associated with fewer hemorrhagic complications and lower mortality while maintaining comparable functional outcomes to standard dosing. These findings support its potential as a safer alternative, particularly in resource-limited settings where cost and drug availability pose challenges. Randomized trials are needed to validate these results.
- 1 September 2023
- Published by ASEAN Neurological Association in Neurology Asia
- Vol. 28 (3) , 535-540
Ticagrelor plus aspirin vs clopidogrel plus aspirin in mild non-cardioembolic ischemic stroke: A protocol of a randomized, controlled, active comparator arm, outcome assessor blind, feasibility study
Background & Objectives: The risk of recurrence after a transient ischemic attack (TIA) or minor stroke is high especially within three months after first event. The aim of study is assessing the efficacy of ticagrelor plus aspirin in reduction of mild non-cardioembolic ischemic stroke or high risk TIA recurrence during first 3 months. Methods: This is a randomized, controlled, active comparator arm, outcome assessor blind, parallel group, feasibility study design on 90 patients with diagnosis of non-cardioembolic minor ischemic stroke or high risk TIA admitted in Bou-Ali Sina Hospital, Sari, Iran. After meeting all inclusion and exclusion criteria, patients will be randomized to ticagrelor 90 mg BID plus aspirin (ASA) 80 mg daily or clopidogrel 75 mg daily plus ASA 80 mg daily (1:1 ratio) until 21 days and then ASA 80 mg daily. Participants will be visited at month one and three. Any adverse events, serious side effects and outcome events will be recorded. The primary outcome is defined as ischemic stroke recurrence. Conclusion: Ticagrelor plus ASA is expected to be effective for prevention of recurrence in mild non-cardioembolic stroke and high risk TIA. Trial Registration: ClinicalTrials.gov: NCT04738097
- 1 September 2023
- Published by ASEAN Neurological Association in Neurology Asia
- Vol. 28 (3) , 535-540
Ticagrelor plus aspirin vs clopidogrel plus aspirin in mild non-cardioembolic ischemic stroke: A protocol of a randomized, controlled, active comparator arm, outcome assessor blind, feasibility study
Background & Objectives: The risk of recurrence after a transient ischemic attack (TIA) or minor stroke is high especially within three months after first event. The aim of study is assessing the efficacy of ticagrelor plus aspirin in reduction of mild non-cardioembolic ischemic stroke or high risk TIA recurrence during first 3 months. Methods: This is a randomized, controlled, active comparator arm, outcome assessor blind, parallel group, feasibility study design on 90 patients with diagnosis of non-cardioembolic minor ischemic stroke or high risk TIA admitted in Bou-Ali Sina Hospital, Sari, Iran. After meeting all inclusion and exclusion criteria, patients will be randomized to ticagrelor 90 mg BID plus aspirin (ASA) 80 mg daily or clopidogrel 75 mg daily plus ASA 80 mg daily (1:1 ratio) until 21 days and then ASA 80 mg daily. Participants will be visited at month one and three. Any adverse events, serious side effects and outcome events will be recorded. The primary outcome is defined as ischemic stroke recurrence. Conclusion: Ticagrelor plus ASA is expected to be effective for prevention of recurrence in mild non-cardioembolic stroke and high risk TIA. Trial Registration: ClinicalTrials.gov: NCT04738097
- Open Access
- 25 November 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Virology
- Vol. 11 (6) , 467-476
Potential risk of liver injury in epileptic patients during COVID-19 pandemic
Potential risk of liver injury in epileptic patients during COVID-19 pandemic
- 25 November 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Virology
- Vol. 11 (6) , 467-476
Open AccessPotential risk of liver injury in epileptic patients during COVID-19 pandemic
Potential risk of liver injury in epileptic patients during COVID-19 pandemic
- Open Access
- 20 November 2022
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 17 (5)
Neurological Manifestations of Hospitalized COVID-19-Infected Patients: A Single-Center Cohort Study
Background: Although COVID-19 preferentially affects the respiratory system, it has been demonstrated that coronaviruses frequently invade the nervous system. Objectives: We aimed to report the frequency and type of neurological manifestations in hospitalized patients with COVID-19. Methods: This is a retrospective, prospective observational cohort study. Data were collected from April to July 2020 at Bu-Ali Sina University Hospital, Sari, Iran. Demographic data and clinical symptoms were recorded at the onset of the disease. Neurological manifestations were recorded into 5 categories: nonspecific central nervous system (CNS) manifestations, acute cerebrovascular disease (CVD), meningitis/encephalitis, peripheral nervous system manifestations, and inflammatory disorders (myelitis and acute disseminated encephalomyelitis). Results: A total of 420 patients were admitted to the hospital with confirmed SARS-CoV-2 infection. Of the 420 patients hospitalized with COVID-19, 282 (67%) showed some form of neurological symptoms, of whom 48.33% had nonspecific neurological symptoms. Further, 35 (8.3%) patients had acute CVD, 2 patients had encephalitis (the RNA of SARS-CoV-2 was detected in cerebrospinal fluid (CSF), 1 patient had myelitis, and 83 (19.76%) patients had peripheral nervous system manifestations. Conclusions: Neurologic symptoms (from mild symptoms to life-threatening CNS disorders) are common in admitted patients with COVID-19. As a result of coagulation disorder in patients with COVID-19, some conditions (such as stroke) can be seen, even during recovery.
- 20 November 2022
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 17 (5)
Open AccessNeurological Manifestations of Hospitalized COVID-19-Infected Patients: A Single-Center Cohort Study
Background: Although COVID-19 preferentially affects the respiratory system, it has been demonstrated that coronaviruses frequently invade the nervous system. Objectives: We aimed to report the frequency and type of neurological manifestations in hospitalized patients with COVID-19. Methods: This is a retrospective, prospective observational cohort study. Data were collected from April to July 2020 at Bu-Ali Sina University Hospital, Sari, Iran. Demographic data and clinical symptoms were recorded at the onset of the disease. Neurological manifestations were recorded into 5 categories: nonspecific central nervous system (CNS) manifestations, acute cerebrovascular disease (CVD), meningitis/encephalitis, peripheral nervous system manifestations, and inflammatory disorders (myelitis and acute disseminated encephalomyelitis). Results: A total of 420 patients were admitted to the hospital with confirmed SARS-CoV-2 infection. Of the 420 patients hospitalized with COVID-19, 282 (67%) showed some form of neurological symptoms, of whom 48.33% had nonspecific neurological symptoms. Further, 35 (8.3%) patients had acute CVD, 2 patients had encephalitis (the RNA of SARS-CoV-2 was detected in cerebrospinal fluid (CSF), 1 patient had myelitis, and 83 (19.76%) patients had peripheral nervous system manifestations. Conclusions: Neurologic symptoms (from mild symptoms to life-threatening CNS disorders) are common in admitted patients with COVID-19. As a result of coagulation disorder in patients with COVID-19, some conditions (such as stroke) can be seen, even during recovery.
- Open Access
- 19 July 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (7) , e6066
Fulminant hepatitis following COVID ‐19 vaccination: A case report
The common side effects of COVID‐19 vaccination were mostly self‐restricted local reactions that quickly resolved. Nevertheless, rare autoimmune hepatitis cases have been reported in some vaccinated with mRNA COVID‐19 vaccines. This article presents a young man who developed fulminant hepatitis a few days after vaccination with the first dose of the AstraZeneca COVID‐19 vaccine. A 35‐year‐old man was admitted to our hospital with generalized weakness, abdominal pain, and jaundice. He received the first dose of the AstraZeneca COVID‐19 vaccine 8 days earlier. He was admitted to the hospital with a chief complaint of abdominal pain. On admission and because of his high D‐dimers, low platelet count, and low Fibrinogen level, vaccine‐induced immune thrombosis thrombocytopenia was suspected, which was ruled out later. Then, after a surge in his liver function tests, decreasing platelet, and abnormal clotting tests, fulminant hepatitis was considered for this patient. Several bacterial, viral, and autoimmune etiologies were then suspected, with all ruled out. Thus, fulminant hepatitis secondary to his AstraZeneca COVID‐19 vaccine was confirmed. Unfortunately, he died 3 days later of disseminated intravascular coagulopathy, after which a liver necropsy was performed, indicating drug/toxin‐induced hepatitis.
- 19 July 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (7) , e6066
Open AccessFulminant hepatitis following COVID ‐19 vaccination: A case report
The common side effects of COVID‐19 vaccination were mostly self‐restricted local reactions that quickly resolved. Nevertheless, rare autoimmune hepatitis cases have been reported in some vaccinated with mRNA COVID‐19 vaccines. This article presents a young man who developed fulminant hepatitis a few days after vaccination with the first dose of the AstraZeneca COVID‐19 vaccine. A 35‐year‐old man was admitted to our hospital with generalized weakness, abdominal pain, and jaundice. He received the first dose of the AstraZeneca COVID‐19 vaccine 8 days earlier. He was admitted to the hospital with a chief complaint of abdominal pain. On admission and because of his high D‐dimers, low platelet count, and low Fibrinogen level, vaccine‐induced immune thrombosis thrombocytopenia was suspected, which was ruled out later. Then, after a surge in his liver function tests, decreasing platelet, and abnormal clotting tests, fulminant hepatitis was considered for this patient. Several bacterial, viral, and autoimmune etiologies were then suspected, with all ruled out. Thus, fulminant hepatitis secondary to his AstraZeneca COVID‐19 vaccine was confirmed. Unfortunately, he died 3 days later of disseminated intravascular coagulopathy, after which a liver necropsy was performed, indicating drug/toxin‐induced hepatitis.
- 20 September 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (12) , 106121
Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
- 20 September 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (12) , 106121
Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
- 30 August 2021
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 19 (4) , 377-382
Outcome of a HIV Positive Patient Infected with COVID-19 After an Autologous Bone Marrow Transplantation: A Case Report
Background: The World Health Organization (WHO) announced the SARS-COV-2 disease pandemic on March 9, 2020. With the advent of this disease, another health burden was added to about 37.9 million people in the world who are infected with HIV and are suffering from various diseases. These people may be at serious risk of COVID-19. Information about the effects of COVID-19 on people living with HIV, is limited. Case Presentation: We reported a 61-year-old man who was a known case of HIV from 6 years ago that was being treated with HAART (highly active antiretroviral therapy). He also had a history of Hodgkin’s lymphoma from 4 years ago who underwent autologous bone marrow transplantation (BMT) 2 weeks before given referral to our hospital. He complained of weakness, anorexia, and fever. RT-PCR for SARS-COV-2-RNA was positive in his nasopharyngeal and oropharyngeal swab. He was diagnosed with COVID-19 infection and treated with atazanavir. After one week, the patient discharged in a good general state. Conclusion: To the best of our knowledge, it is the first report of COVID-19 infection in an HIV positive patient after BMT in Iran. Despite his immunodeficiency, COVID-19 disease had mild manifestations and he had a good prognosis. We hope that our report and that of others can remain promising to doctors and HIV patients cross fingers for COVID-19 recovery.
- 30 August 2021
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 19 (4) , 377-382
Outcome of a HIV Positive Patient Infected with COVID-19 After an Autologous Bone Marrow Transplantation: A Case Report
Background: The World Health Organization (WHO) announced the SARS-COV-2 disease pandemic on March 9, 2020. With the advent of this disease, another health burden was added to about 37.9 million people in the world who are infected with HIV and are suffering from various diseases. These people may be at serious risk of COVID-19. Information about the effects of COVID-19 on people living with HIV, is limited. Case Presentation: We reported a 61-year-old man who was a known case of HIV from 6 years ago that was being treated with HAART (highly active antiretroviral therapy). He also had a history of Hodgkin’s lymphoma from 4 years ago who underwent autologous bone marrow transplantation (BMT) 2 weeks before given referral to our hospital. He complained of weakness, anorexia, and fever. RT-PCR for SARS-COV-2-RNA was positive in his nasopharyngeal and oropharyngeal swab. He was diagnosed with COVID-19 infection and treated with atazanavir. After one week, the patient discharged in a good general state. Conclusion: To the best of our knowledge, it is the first report of COVID-19 infection in an HIV positive patient after BMT in Iran. Despite his immunodeficiency, COVID-19 disease had mild manifestations and he had a good prognosis. We hope that our report and that of others can remain promising to doctors and HIV patients cross fingers for COVID-19 recovery.